Emerging therapeutics in the management of connective tissue disease. Part II: Dermatomyositis and scleroderma.

Authors :: Kodumudi V
Bibb LA
Adalsteinsson JA
Shahriari N
Skudalski L
Santiago S
Grant-Kels JM
Lu J
Source :: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2022 Jul; Vol. 87 (1), pp. 21-38. Date of Electronic Publication: 2022 Feb 22.
Publication Year :: 2022
Abstract: The management of connective tissue diseases is dramatically evolving with the advent of biologics and novel oral systemic therapeutics. Despite involvement in the care of these complex patients, there is a knowledge gap in the field of dermatology regarding these emerging agents. The second article in this continuing medical education series discusses new and emerging therapeutics for dermatomyositis and scleroderma that target cells, intracellular signaling pathways, and cytokines.<br />Competing Interests: Conflicts of interest None disclosed.<br /> (Copyright © 2022 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)

Subjects :: Humans
Connective Tissue Diseases therapy
Dermatomyositis drug therapy
Scleroderma, Localized drug therapy
Scleroderma, Systemic therapy

Full Text Access

Tools